Author: da Cunha, Gilmara Franco; de Souza, Fernando Henrique Carlos; Levy-Neto, Maurício; Shinjo, Samuel Katsuyuki
Title: Chloroquine diphosphate: a risk factor for herpes zoster in patients with dermatomyositis/polymyositis Document date: 2013_5_23
ID: s9mqzqu4_20
Snippet: There was no difference between DM/PM with and without HZ with regard to glucocorticoid therapy (current use, medium dose and cumulative dose over the two previous months). Similarly, immunosuppressive therapy use was similar in both groups (Table 4 ). However, the patients using chloroquine diphosphate had a 5.98-fold (95% CI, 1.66-22.26) greater risk of developing HZ compared to the patients who did not receive chloroquine diphosphate treatment.....
Document: There was no difference between DM/PM with and without HZ with regard to glucocorticoid therapy (current use, medium dose and cumulative dose over the two previous months). Similarly, immunosuppressive therapy use was similar in both groups (Table 4 ). However, the patients using chloroquine diphosphate had a 5.98-fold (95% CI, 1.66-22.26) greater risk of developing HZ compared to the patients who did not receive chloroquine diphosphate treatment.
Search related documents:
Co phrase search for related documents- chloroquine diphosphate and diphosphate treatment: 1
- chloroquine diphosphate and medium dose: 1
- chloroquine diphosphate treatment and diphosphate treatment: 1
- cumulative medium dose and medium dose: 1
- glucocorticoid therapy and medium dose: 1, 2
Co phrase search for related documents, hyperlinks ordered by date